Roundhill GLP-1 & Weight Loss ETF · NASDAQ:OZEM
Roundhill GLP-1 & Weight Loss ETF — Investor Presentation (June 2024)
9 slides from Roundhill GLP-1 & Weight Loss ETF's investor presentation, June 2024
Slide 1: OZEM GLP-1 & Weight Loss ETF Investment Case
OZEM GLP-1 & Weight Loss ETF Investment Case June 2024
Slide 2: Foreside Fund Services, LLC: Distributor
Foreside Fund Services, LLC: Distributor 0 Investors should consider the investment objectives, risk, charges and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about The Roundhill GLP-1 & Weight Loss ETF please call 1-877-220-7649 or visi
Slide 3: Table of Contents
Table of Contents GLP-1 Overview Market Opportunity * Obesity Epidemic * Revolutionary Drugs + Market Growth Introducing OZEM
Slide 4: GLP-1 Overview
GLP-1 GVERview What are GLP-1 Drugs? GLP-1 receptor agonists represent a transformative advancement in the fight against obesity, a growing global health crisis. These medications function by mimicking the activity of the naturally occurring hormone GLP-1, which helps regulate blood sugar and decrea
Slide 5: Market Opportunity: Obesity Epidemic
Market Opportunity: Obesity Epidemic Rising obesity rates worldwide are straining healthcare systems economically. According to the WHO, global obesity rates have nearly tripled since 1975 and are projected to impact over half the global population by 2035, compared to 38% in 2020. The United States
Slide 6: Market Opportunity: Revolutionary Drugs
Market Opportunity: REVOlUnOnary Drugs GLP-1 treatments are at the cutting-edge of medical advancements in weight management. These treatments have shown transformative effects on weight loss and metabolic health, with drugs like Ozempic, Wegovy, Zepbound, and Mounjaro leading the charge. Wegovy, sp
Slide 7: Market Opportunity: Market Growth
Market Opportunity: Market Growth The obesity treatment market is set for explosive growth. Goldman Sachs Research forecasts that by 2030, the market could reach $130 billion! This growth is driven by increasing global obesity rates, which are expected to impact one in four people by 2035. For infor
Slide 8: Introducing OZEM: Reasons to consider OZEM ETF
Introducing GZEME The GLP-1 & Weight Loss ETF P| 3 Reasons to consider OZEM ETF: . . . . Market Growth Obesity Epidemic Revolutionary Drugs Global obesity rates have nearly Groundbreaking GLP-1 treatments, such Boleman Sachs Research forecasts thet tripled since 1975 and are projected as Ozempic, We
Slide 9: OZEM — Roundhill
OZEM — Roundhill GLP-1 & Weight Loss ETF Investors should consider the investment objectives, risk, charges and expenses carefully before investing, For a prospectus or summary prospectus with this and other information about Roundhill ETFs please call 1855-561-5728 or visit the website at www.round
Roundhill GLP-1 & Weight Loss ETF (OZEM) — Investor Presentation (June 2024) on 6ix